Caribou Biosciences, Inc. (CRBU) News
Filter CRBU News Items
CRBU News Results
|Loading, please wait...|
CRBU News Highlights
- For CRBU, its 30 day story count is now at 2.
- Over the past 26 days, the trend for CRBU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NICE are the most mentioned tickers in articles about CRBU.
Latest CRBU News From Around the Web
Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.
BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to participate in the following investor conferences: Guggenheim Oncology Conference 2023, New York CityFebruary 9, 2023, 10:45 am ESTWebcast SVB Securities Global Biopharma Conference, virtualFebruary 14, 2023, 5:00 pm ESTWebcast
Even in a risk-off market, gene editing stocks look attractive.
Investors in Caribou Biosciences (NASDAQ:CRBU) from a year ago are still down 46%, even after 11% gain this past week
It's nice to see the Caribou Biosciences, Inc. ( NASDAQ:CRBU ) share price up 11% in a week. But that is minimal...
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 am PST. A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The
ANTLER Phase 1 trial of CB-010 at dose level 1 12-month clinical data from cohort 1 in the ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x10^6 CAR-T cells) -- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r/r B-NHL -- -- ANTLER trial enrolling patients at dose level 3 -- BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen CRISPR technology to engineer and advance both CAR-NK and CAR-T cell therapy programs -- BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced target selection for CB-020, an
Positive week for Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional investors who lost 50% over the past year
A look at the shareholders of Caribou Biosciences, Inc. ( NASDAQ:CRBU ) can tell us which group is most powerful. And...
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
-- RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial -- -- CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout -- BERKELEY, CA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted CB-010 Regenerative Medicine Advanced Therap
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences (CRBU - Research Report) today and set a price target of $27.00. The company's shares closed last Friday at $9.08.Burns covers the Healthcare sector, focusing on stocks such as MacroGenics, Neoleukin Therapeutics, and Y-Mabs Therapeutics. According to TipRanks, Burns has an average return of -24.1% and a 22.68% success rate on recommended stocks. Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $27.33, which is a 200.99% upside from current levels.
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
CB-011 CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking. CB-011 Immune Cloaking CB-011 is engineered to improve persistence of antitumor response through an immune cloaking genome-editing approach that removes the B2M protein and inserts a B2M–HLA-E fusion protein. -- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is engineered with a differentiated immune cloaking strategy, designed to enhance pe